Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
about
Geranylgeranyl diphosphate synthase: an emerging therapeutic targetLoss of RhoB expression enhances the myelodysplastic phenotype of mammalian diaphanous-related Formin mDia1 knockout miceProteomic analysis of bovine brain G protein gamma subunit processing heterogeneity.Sequence dependence and differential expression of Ggamma5 subunit isoforms of the heterotrimeric G proteins variably processed after prenylation in mammalian cells.JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.Inhibition of the CaaX proteases Rce1p and Ste24p by peptidyl (acyloxy)methyl ketones.Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies.Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways.Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas.Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.Oncogenic K-ras cooperates with PML-RAR alpha to induce an acute promyelocytic leukemia-like disease.Tipifarnib in the treatment of acute myeloid leukemia.Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
P2860
Q28252056-F33789F1-23A9-4597-B033-B65779EF13B3Q28476172-4B1E821A-95C2-4C36-90D9-15921FCB633AQ33228701-DA05DE74-DCBF-4BCB-8483-4F2CC10A01FFQ33278014-ADE5624B-56A1-4977-8BE5-3F353E0D0814Q35635353-3AC6CCD1-3D8A-430C-90BB-FFE67D640058Q35990361-8781999A-5FE7-4378-BB00-5A4E67524ED5Q36461618-14346641-1A30-4535-9BA6-D05A154C8C06Q37051428-225ACBBF-856C-4E3A-A23B-520B33291CC5Q37616238-06DD8CDC-262B-4FC5-BEBE-4E058C022D4DQ39305389-814CAB10-66E4-4268-A758-45BDC84275ACQ39998302-25D4FB63-0F20-4179-9769-F8A3720727ADQ42082533-F788B543-5CCE-4027-9719-105C1FB812CAQ42217527-A8E4AB7D-0342-4FBB-8D91-B999EF166F9CQ46698294-6ED83712-6EA4-41F2-931E-A01367F7B8A3
P2860
Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
@ast
Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
@en
type
label
Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
@ast
Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
@en
prefLabel
Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
@ast
Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
@en
P2093
P2860
P356
P1433
P1476
Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403024
P577
2003-08-01T00:00:00Z